BACKGROUND: Optimal timing of antiretroviral therapy in HIV-infected persons is unclear, although 2 recent large observational studies have improved our understanding of the best CD4 threshold for initiation. These studies compared the effect of starting HAART on mortality and mortality/AIDS between strata defined using broad ranges of CD4 counts. We sought to expand this understanding using a novel statistical approach proposed by Robins et al. METHODS: Using observational data from 1034 antiretroviral-naive HIV-infected patients from Nashville, Tennessee, we directly estimated the optimal CD4 count for initiation of HAART to maximize patient health 6, 12, 24, and 36 months after the first instance of CD4 falling below 750. We measured health using 2 outcome metrics, one based on CD4 counts at the end of follow-up and the other based on a published quality-of-life scale; both metrics incorporated death, AIDS-defining events, serious non-AIDS events, and CD4 at the end of follow-up, if asymptomatic. RESULTS: The CD4-based metric estimated that to maximize health 6, 12, 24, and 36 months after study entry, HAART should be initiated within 3 months of CD4 first dropping below 495 (95% confidence interval [CI] = 468-522), 554 (459-750), 489 (427-750), and 509 (460-750), respectively. The quality-of-life-based metric produced CD4 initiation threshold estimates of 337 (95% CI = 201-442), 354 (288-386), 358 (294-750), and 475 (287-750) for the same time points. CONCLUSIONS: Our results support early initiation of antiretroviral therapy, although the criterion for starting therapy depends on the choice of health outcome.
BACKGROUND: Optimal timing of antiretroviral therapy in HIV-infectedpersons is unclear, although 2 recent large observational studies have improved our understanding of the best CD4 threshold for initiation. These studies compared the effect of starting HAART on mortality and mortality/AIDS between strata defined using broad ranges of CD4 counts. We sought to expand this understanding using a novel statistical approach proposed by Robins et al. METHODS: Using observational data from 1034 antiretroviral-naive HIV-infectedpatients from Nashville, Tennessee, we directly estimated the optimal CD4 count for initiation of HAART to maximize patient health 6, 12, 24, and 36 months after the first instance of CD4 falling below 750. We measured health using 2 outcome metrics, one based on CD4 counts at the end of follow-up and the other based on a published quality-of-life scale; both metrics incorporated death, AIDS-defining events, serious non-AIDS events, and CD4 at the end of follow-up, if asymptomatic. RESULTS: The CD4-based metric estimated that to maximize health 6, 12, 24, and 36 months after study entry, HAART should be initiated within 3 months of CD4 first dropping below 495 (95% confidence interval [CI] = 468-522), 554 (459-750), 489 (427-750), and 509 (460-750), respectively. The quality-of-life-based metric produced CD4 initiation threshold estimates of 337 (95% CI = 201-442), 354 (288-386), 358 (294-750), and 475 (287-750) for the same time points. CONCLUSIONS: Our results support early initiation of antiretroviral therapy, although the criterion for starting therapy depends on the choice of health outcome.
Authors: Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán Journal: Int J Biostat Date: 2010 Impact factor: 0.968
Authors: Stephen R Cole; Rui Li; Kathryn Anastos; Roger Detels; Mary Young; Joan S Chmiel; Alvaro Muñoz Journal: Stat Med Date: 2004-11-15 Impact factor: 2.373
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: K A Freedberg; J A Scharfstein; G R Seage; E Losina; M C Weinstein; D E Craven; A D Paltiel Journal: JAMA Date: 1998-01-14 Impact factor: 56.272
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: James E Bailey; David L Van Brunt; Stephen P Raffanti; Wendy J Long; Patrick H Jenkins Journal: Am J Manag Care Date: 2003-09 Impact factor: 2.229
Authors: C William Wester; John R Koethe; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Hwanhee Hong; Hermann Bussmann; Tendani Gaolathe; Catherine C McGowan; Timothy R Sterling; Richard G Marlink Journal: AIDS Date: 2011-07-31 Impact factor: 4.177
Authors: Jason F Okulicz; Tuan D Le; Brian K Agan; Jose F Camargo; Michael L Landrum; Edwina Wright; Matthew J Dolan; Anuradha Ganesan; Tomas M Ferguson; Davey M Smith; Douglas D Richman; Susan J Little; Robert A Clark; Weijing He; Sunil K Ahuja Journal: JAMA Intern Med Date: 2015-01 Impact factor: 21.873
Authors: Bryan E Shepherd; Qi Liu; Nathaniel Mercaldo; Cathy A Jenkins; Bryan Lau; Stephen R Cole; Michael S Saag; Timothy R Sterling Journal: Stat Med Date: 2016-06-06 Impact factor: 2.373
Authors: Maarten J IJzerman; Julie A Simpson; Robert K Mahar; Myra B McGuinness; Bibhas Chakraborty; John B Carlin Journal: BMC Med Res Methodol Date: 2021-02-22 Impact factor: 4.615